|
||||||||||||||
|
|
Multimodality Low Dose Chemotherapy The goal of chemotherapy in the treatment of cancer is to shrink primary tumors, slow the tumor growth, and kill cancer cells that may have spread (metastasized) to other parts of the body from the original, primary tumor. The underlying conventional rational has been to use the most effective chemo or chemo combinations at as high a dose possible in order to kill the most cancer cells... without killing the patient. Chemotherapy kills both cancer and healthy cells. Oncologists try to minimize damage to normal cells and to enhance the cytotoxic effect on cancer cells. Too often, unfortunately, this delicate balance is not achieved. Chemotherapy drugs in general have a high rate of failure, that is, because these drugs are unable to penetrate the tumor site, or usually kill only specific types of cancer cells within a tumor, or the cancer cells mutate and become resistant to the chemotherapy. Respected cancer journals are publishing articles that identify safer and more effective treatment regimens combining different therapeutic modalities, yet few oncologists are incorporating these synergistic methods into their clinical practice. Cancer patients still suffer through chemotherapy sessions that do not integrate the latest scientific findings. The objective of this article is to provide the patient with more options to consider and discuss with their oncologist or holistic health professional about using multimodality approaches to improve the probability of a successful outcome. Low dose targeted Chemotherapy: Some studies indicate that a more scientific approach would be to lower the dose of conventional cytotoxic agents, reschedule their application, and combine chemotherapy drugs with a targeting agent that directs them directly to cancer cells. Because of the altered status of the tumor, its anaerobic metabolism, and its abnormal vasculature, only a small portion of the tumor is affected by cytotoxic drugs. However, simply by mixing them physically with hyaluronic acid, HA, they loosely combine and will target the sites where HA is deficient and across the blood brain barrier. Investigations have moreover shown that tumors possess several HA receptors (CD44, RHAMM, etc.). This fact explains that HA will help cytotoxic drugs act specifically with the tumor cells, thus reducing their side effects on other normal cells. 1 Angiogenesis inhibition: Another therapeutic target is the endothelial cells that form new blood vessels around tumors. The process by which new blood vessels are formed is called angiogenesis, and cancer cells initiate blood vessel proliferation in order to fuel rapid growth. Agents that interfere with the formation of new blood vessels are an important part of a comprehensive treatment strategy. They effectively interfere with cancer's various growth pathways and inhibit the production of blood vessels. 2 Non steroidal anti- inflammatories (NSAID’S) and COX II inhibitors combined with Hyaluronic acid and vitamin C present a very efficient action on the cancerous endothelial cells. This is mediated through the ICAM 1 receptors. 3 They also markedly help reduce cancer related pain and assist patients in avoiding morphine. Other angiogenesis agents include curcumin, green tea, etc. Poly MVA This compound is a non-toxic polynucleotide reductase named POLYDOX (USA trials), Poly-MVA (Canada and Mexico) or LAPd by some researchers. The MVA stands for minerals, vitamins, and amino acids. LAPd stands for Lipoic acid / Palladium complex. Lipoic acid is a natural powerful antioxidant that is both water and fat soluble, which permits the Poly-MVA to pass across the cell membranes and the blood brain barrier, which is impossible for most drugs, including chemotherapy. Cancer cells have deranged respiration producing less water in the cell and utilizing more sugar, and one-twentieth the oxygen of normal cells and no oxygen radical pathways. Thus when synthetic DNA reductase enters these cells, protein radicals are formed which denature the tumor cell’s proteins. Since “normal cells” are capable of converting the radicals into energy and water, no harm can occur. The most dramatic responses were noted with brain tumors. Other tumors that respond well are breast, ovarian, prostate, colon, and lung cancer, among others. The original human trials were done in Canada by the late oncologist, Dr. Rudy Falk, usually in conjunction with standard chemotherapy for more than five years. He reported benefits including tumor shrinkage, pain reduction or control, improved appetite and weight gain, and increasing energy. Some patients are still using low doses of Poly-MVA and have no signs of cancer after ten years of use.1 To complete the above-mentioned protocol, the following tools are used: Immune System Stimulants and Modulators: Immpower, MGN III, IP 6, AG Immune, NK cell, Thymus, placenta, Iscador, etc. Detoxification: Glutathione, Milk thistle, Colonics, Infra-red sauna, coffee enemas, etc. Oxygenation Therapy: Ozone autohemotherapy, Hydrogen Peroxide, etc. Fibrin cancer cells coat digestion: Wob mugos 4, Wobenzyme, etc. Energy healing: Meditation, Relaxation, Reiki, Hypnotherapy, etc. Finally, I hope that this researched information will help the cancer patients to be more informed before deciding what to do at the moment when they are diagnosed, and assist them in choosing the most effective treatment modality with the least side eff 1- Poly-MVA, Cancer Breakthrough, Al Sanchez. AMARC: Chula Vista, California 91910. 2- Holland et al. 2000. 3- Third International Worksahop on hyaluronan in drig delivery, Switzerland March 31st-April 1st 1995. 4- Oral enzymes- New approach to cancer treatment. F. Klaschka, MD, 1996. |
|
||||||||||||
|
||||||||||||||